On the recordNovember 16, 2015
And so is it fair to conclude that your assessment is that the transparency related to your relationship with the pharmaceutical company, that it could produce higher costs for the consumer?
Source
congress.govEditor's note · Context
Cicilline questions the impact of transparency on pharmaceutical costs.
Share
More from David Cicilline
Apr 25, 2023
I rise in opposition to H.R. 1690 and associate myself with the remarks of Mr. Connolly.
May 16, 2023
Democracies consistently prove to be the most reliable geopolitical allies and trading partners for our country.
Jul 6, 2026
You can’t have a statewide school funding system that is fair to everyone — that’s equitable, that covers all costs of education, so that every student, no matter where they live, is treated the same, and every taxpayer treated the same —…
Apr 26, 2023
With Section 702 set to sunset at the end of this year it is vital that we have these discussions before we take our next steps.
Other voices in this conversation
